Immunotherapy targeting the programmed cell death protein 1/programmed cell death ligand 1 (PD1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) immune checkpoint signaling has proven to be successful in the treatment of various metastatic tumors [11]. The gene discussed is PDCD1; the disease is metastatic neoplasm.